BR112018071031A2 - combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr - Google Patents

combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr

Info

Publication number
BR112018071031A2
BR112018071031A2 BR112018071031-8A BR112018071031A BR112018071031A2 BR 112018071031 A2 BR112018071031 A2 BR 112018071031A2 BR 112018071031 A BR112018071031 A BR 112018071031A BR 112018071031 A2 BR112018071031 A2 BR 112018071031A2
Authority
BR
Brazil
Prior art keywords
targeting
combinations
target cells
treating neoplasms
egfr inhibitors
Prior art date
Application number
BR112018071031-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Vilenchik Maria
Frid Michael
Kuznetsova Alexandra
Gankin Yuriy
Duey Marc
Original Assignee
Felicitex Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicitex Therapeutics, Inc. filed Critical Felicitex Therapeutics, Inc.
Publication of BR112018071031A2 publication Critical patent/BR112018071031A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018071031-8A 2016-04-15 2017-04-14 combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr BR112018071031A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
US62/323,537 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Publications (1)

Publication Number Publication Date
BR112018071031A2 true BR112018071031A2 (pt) 2019-02-12

Family

ID=60039950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071031-8A BR112018071031A2 (pt) 2016-04-15 2017-04-14 combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr

Country Status (11)

Country Link
US (3) US10322128B2 (OSRAM)
EP (1) EP3442505A4 (OSRAM)
JP (2) JP7123806B2 (OSRAM)
KR (2) KR20230020565A (OSRAM)
CN (1) CN109562176A (OSRAM)
AU (2) AU2017248762A1 (OSRAM)
BR (1) BR112018071031A2 (OSRAM)
CA (1) CA3021021A1 (OSRAM)
IL (2) IL262323B (OSRAM)
MX (2) MX2018012511A (OSRAM)
WO (1) WO2017181075A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120349A1 (en) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
BR112018071023A2 (pt) 2016-04-15 2019-02-05 Felicitex Therapeutics Inc combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
KR20200135743A (ko) * 2019-05-22 2020-12-03 보로노이 주식회사 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
WO2022265950A1 (en) * 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
CA3242316A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
PL2744797T3 (pl) * 2011-08-19 2016-01-29 Diaxonhit Inhibitory dyrk1 i ich zastosowanie
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
PE20170127A1 (es) 2014-03-20 2017-03-30 Samumed Llc Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
CN108135871B (zh) * 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
BR112018071023A2 (pt) 2016-04-15 2019-02-05 Felicitex Therapeutics Inc combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose

Also Published As

Publication number Publication date
AU2023200428A1 (en) 2023-03-02
EP3442505A4 (en) 2019-12-18
AU2017248762A1 (en) 2018-11-01
WO2017181075A1 (en) 2017-10-19
US20190298723A1 (en) 2019-10-03
US11202779B2 (en) 2021-12-21
CN109562176A (zh) 2019-04-02
IL288777A (en) 2022-02-01
JP7123806B2 (ja) 2022-08-23
KR20180132882A (ko) 2018-12-12
MX2023000549A (es) 2023-02-13
CA3021021A1 (en) 2017-10-19
MX2018012511A (es) 2019-07-08
KR20230020565A (ko) 2023-02-10
IL262323A (en) 2018-11-29
KR102494174B1 (ko) 2023-02-02
JP2019511554A (ja) 2019-04-25
US10322128B2 (en) 2019-06-18
JP2022145800A (ja) 2022-10-04
US20170296541A1 (en) 2017-10-19
EP3442505A1 (en) 2019-02-20
IL262323B (en) 2022-03-01
US20220110940A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2022012146A (es) Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX393976B (es) Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.
BR112017008628A2 (pt) terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
MX359227B (es) Tratamiento de cáncer con inhibidores de tor cinasa.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX381582B (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
MX385315B (es) Composiciones y metodos para inhibir actividad de arginasa.
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]